01477nas a2200361   4500000000100000008004100001260001300042653002700055653001200082653004100094653001200135653002200147653002300169653001200192653000900204653002400213653003200237653002500269653001800294653001400312653001700326100001500343700001400358700001600372700001800388700001800406700001500424245013500439300001000574490000700584520051000591022001401101       1990                            d  c1990 Jan10aAdenosine Triphosphate10aAnimals10aChromatography, High Pressure Liquid10aDapsone10aDrug Interactions10aLeprostatic Agents10aleprosy10aMice10aMice, Inbred BALB C10aMicrobial Sensitivity Tests10aMycobacterium leprae10aReceptors, Fc10aThymidine10aTrimethoprim1 aSeydel J K1 aWempe E G1 aRosenfeld M1 aJagannathan R1 aMahadevan P R1 aDhople A M00aIn vitro and in vivo experiments with the new inhibitor of mycobacterium leprae brodimoprim alone and in combination with dapsone.  a69-750 v403 a<p>The antibacterial effect of brodimoprim alone and in combination with dapsone has been studied in vitro in cell-free systems and in whole mycobacterial cells as well as in vivo in mice and humans. The obtained inhibitory effects in vitro and in vivo against model mycobacterial strains and M. leprae, the pharmacokinetic properties in human and its synergistic effect with the most used drug in the chemotherapy of leprosy, dapsone, make brodimoprim a promising candidate in the therapy of leprosy.</p>  a0004-4172